Original White Feather Rice Intranet
Highlights
On July 25, Luoxin Pharmaceutical announced that its subsidiary, Shandong Luoxin Lekang Pharmaceutical, had been approved for a supplementary application for consistency evaluation of montmorillonite powder. According to data from Minenet, montmorillonite will have a sales scale of more than 1 billion yuan in China's three major terminals and six major markets in 2023 (see the statistical scope at the end of the article). In addition, its subsidiary, Shandong Luoxin Pharmaceutical Group, has been approved for the supplementary application for consistency evaluation of cefoperazone sodium sulbactam sodium for injection 2.0g.
Montmorillonite powder was developed by IPSEN PHARMA for acute and chronic diarrhea in adults and acute diarrhea in children.
Sales of montmorillonite powder in retail pharmacies in China in recent years (unit: 100 million yuan)
Source: Minenet Grid Bureau Database
In 2023, montmorillonite scatter will have a sales scale of more than 1 billion yuan in China's three major terminals and six major markets, of which the out-of-hospital market (retail pharmacy terminals: urban physical pharmacies + online pharmacies) is the main sales channel, with a year-on-year increase of more than 60%, and is the TOP2 product of antidiarrheal drugs and intestinal anti-inflammatory/anti-infective drugs, with the largest market share of Ipsen in France.
According to the data of Minenet, there are 44 companies with production approvals for montmorillonite, 35 companies such as Shandong Luoxin Lekang Pharmaceutical, Hunan Sheng Pharmaceutical, and Yangtze River Pharmaceutical Group have been evaluated, and there is no supplementary application for consistency evaluation under review, and 5 companies such as Fujian Pacific Pharmaceutical and Sichuan Yike Pharmaceutical are under review for imitation 4 types of production, and they will be deemed to have passed the evaluation after approval.
Luoxin Pharmaceutical's digestive system and metabolic drugs have been over-evaluated
Source: Intranet Consistency Evaluation Database
Up to now, 11 products of Luoxin Pharmaceutical have passed/deemed to have passed the consistency evaluation in the field of digestive system and metabolic drugs. Four products, including omeprazole sodium for injection, omeprazole enteric-coated capsules, and esomeprazole magnesium enteric-coated tablets, will be 1 billion varieties in China's three major terminals and six major markets in 2023.
Source: Company announcements, Minenet database
Note: The statistical scope of "Drug Competition Pattern of China's Three Terminals and Six Major Markets" by Minenet is: urban public hospitals and county-level public hospitals, urban community centers and township health centers, urban physical pharmacies and online pharmacies, excluding private hospitals, private clinics, village clinics, and county and rural pharmacies; The above sales are calculated based on the average retail price of the product at the terminal. If there is any omission, please correct it!